MBMarta Maia Bosca-Watts

Marta Maia Bosca-Watts

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marta Maia Bosca-Watts has a total of 570 co-authors. Here are the top co-authors by number of shared publications:

  • María Chaparro

    Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) , Madrid

    10 shared publications
  • José María Huguet

    Department of Gastroenterology, Hospital General Universitario de Valencia, Valencia, Spain

    9 shared publications
  • Marisa Iborra

    Inflammatory Bowel Disease Research Group, Health Research Institute La Fe (IIS La Fe), IBD Unit, Gastroenterology Department, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain

    9 shared publications
  • Javier P. Gisbert

    Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) , Madrid

    8 shared publications
  • Francisco Mesonero

    Department of Gastroenterology Hospital Universitario Ramón y Cajal Madrid Spain

    7 shared publications
  • Miguel Minguez

    AEG y SEPD, Hospital Clínico Universitario, Universitat de Valencia, Valencia, España

    7 shared publications

Latest Publications

  • Impact of Inflammatory Activity on Anorectal Function in Patients With Ulcerative Colitis: A Prospective Study

    by Ana Sanahuja Martínez, Pilar Mas Mercader, Joan Tosca Cuquerella, Marta Maia Boscá Watts, Maria Rosario Antón Ausejo, Carles Suria Bolufer, Víctor Merino Murgui, David Moro Valdezate, Stephanie García Botello, Isabel Pascual Moreno, et al.

    Objectives: Anorectal symptoms are common in ulcerative colitis (UC), yet the impact of inflammatory activity on anorectal function remains unclear. We evaluated the relationship between inflammatory activity and anorectal function and its effect on symptom development. Methods: We conducted a prospective observational study on patients with UC and active disease attending our center. Clinical, biochemical, and endoscopic assessments were performed together with high‐resolution anorectal manometry (HR‐ARM) and rectal electronic barostat testing at two time points: during active disease and 4–6 months after treatment initiation. Results: Thirty‐six UC patients and 10 healthy volunteers were included. During active disease, fecal incontinence (FI), urgency, and tenesmus were reported by 66.7%, 91.7%, and 83.3% of patients, respectively. After treatment, symptoms improved; however, a subset of patients remained symptomatic: 32.3% still reported FI, 54.8% urgency, and 51.6% tenesmus. Greater endoscopic and histological activity correlated with lower sensory thresholds and reduced rectal capacity and compliance (all p < 0.05). The Mayo endoscopic subscore correlated inversely with desire to defecate volume ( ρ = −0.41, p = 0.014) and maximum tolerated volume ( ρ = −0.53, p = 0.001) and positively with anal pressure during the defecatory manoeuver ( r = 0.35, p = 0.037). Barostat parameters remained altered after treatment compared with healthy controls, including in patients who achieved histological remission. Conclusions: Inflammatory activity in UC impairs anorectal function by increasing rectal sensitivity and reducing rectal compliance and capacity, contributing to persistent symptoms. Ongoing dysfunction after remission highlights the need for diagnostic and therapeutic strategies addressing anorectal involvement.

  • Open Access

    Decanoic acid in Crohn’s disease-associated complications: Antifibrotic effect mediated by PPARγ

    by Andrea Cejudo-Garcés, Jalpa Patel, Ana Jarén, Marta Maia Boscá-Watts, Sara Calatayud, María Dolores Barrachina, Dolores Ortiz-Masiá, Jesús Cosín-Roger


  • Persistence, Effectiveness, and Safety of Upadacitinib in Crohn's Disease and Ulcerative Colitis in Real Life: Results From a Spanish Nationwide Study (Ureal Study)

    by María José García, Yanire Brenes, Miren Vicuña, Fernando Bermejo, Mónica Sierra-Ausín, Raquel Vicente, María Teresa Arroyo, Pilar Martínez Montiel, Albert Villoria, Juan Ángel Ferrer, et al.

    INTRODUCTION: Real-world data on the effectiveness of upadacitinib for inflammatory bowel disease (IBD) are limited. To assess upadacitinib persistence, effectiveness, and safety in a real-world scenario. METHODS: Retrospective multicenter study of patients with IBD who received upadacitinib before 31st December 2022 and at least 12 weeks before the recruitment date. Clinical effectiveness was assessed based on partial Mayo score for ulcerative colitis (UC) and Harvey–Bradshaw index for Crohn's disease (CD). RESULTS: We included 100 patients (68 with CD, and 32 with UC). Patients had previously received a median of 4 advanced therapies. Twenty-three discontinued the treatment (median follow-up 7.6 months). CD (vs UC) (hazard ratio 3.7; 95% confidence interval [CI]: 1.04–12.9) and age below 40 years at upadacitinib initiation (hazard ratio 2.4; 95% CI: 1.0–5.8) were associated with treatment discontinuation in multivariable analysis. Clinical remission for IBD was achieved in 59% of patients at week 8, 64% at week 12, and 42% at week 52. The proportion of patients with UC previously exposed to tofacitinib (n = 25) who achieved clinical remission was 78% at week 12, and 50% at week 52. Factors associated with clinical remission at week 12 were UC diagnosis (odds ratio [OR] 4.6; 95% CI: 1.3–17), mild or moderate activity at baseline (OR 8; 95% CI: 1.1–56), and not smoking (OR 4.4; 95% CI: 1.5–13). Dose escalation recaptured remission in 60% of patients with relapse. Eighty percent of patients with active immune-mediated diseases or extraintestinal manifestations improved with upadacitinib. Forty-three patients reported adverse events, 11 of them serious. DISCUSSION: Upadacitinib is effective and safe for treating patients with highly refractory IBD, even in previously treated with Janus kinase inhibitors.


  • Open Access

    Long‐term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study

    by María Chaparro, Sandra Hermida, Diana Acosta, Agnès Fernández‐Clotet, Manuel Barreiro‐De Acosta, Álvaro Hernández Martínez, Maite Arroyo, Marta Maia Bosca‐Watts, M. Teresa Diz‐Lois Palomares, Luis Menchén, et al.

    Summary: Background: Ustekinumab is approved for ulcerative colitis (UC).Aims: To assess the durability of ustekinumab in patients with UC and its short‐term effectiveness, durability and tolerability in clinical practice.Methods: Retrospective, multicentre study of patients who had received their first ustekinumab dose at least 16 weeks before inclusion. Patients were followed until treatment discontinuation or last visit. Only patients with active disease at the start of ustekinumab treatment were considered in the effectiveness analysis. Patients who stopped ustekinumab before their last visit were considered not to be in subsequent remission.Results: We included 620 patients; 155 (25%) discontinued ustekinumab during follow‐up (median 12 months). Rate of discontinuation was 20% per patient‐year of follow‐up. Anaemia at baseline (hazard ratio, HR 1.5; 95% confidence interval [CI] 1.1–2.1), steroids at baseline (HR 1.5; 95% CI 1.06–2.08) and more severe clinical activity at baseline (HR 1.5; 95% CI 1.09–2.06) were associated with higher risk of discontinuation. At the end of induction, 226 (40%) patients were in steroid‐free clinical remission. Moderate–severe vs mild disease activity at baseline (odds ratio [OR] 0.3; 95% CI 0.2–0.5), male sex (OR 0.5; 95% CI 0.4–0.8), and increased number of previous biologics (OR 0.6; 95% CI 0.6–0.8) were associated with lower likelihood of steroid‐free clinical remission at week 16. One hundred and seventy‐six patients (28%) had at least one adverse event. We observed no negative impact of ustekinumab on extraintestinal manifestations and/or immune‐mediated diseases.Conclusions: Ustekinumab durability in UC was relatively high, and treatment was effective in highly refractory patients. The safety profile was consistent with previous studies.


  • Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA Registry

    by Marisa Iborra, Berta Caballol, Alejandro Garrido, José María Huguet, Francisco Mesonero, Ángel Ponferrada, Lara Arias García, Marta Maia Boscá Watts, Samuel J Fernández Prada, Eduard Brunet Mas, et al.

    Background and Aims: Switching from intravenous infliximab (IV-IFX) to subcutaneous biosimilar infliximab (SC-IFX) has been shown to safely maintain clinical remission and increase drug levels in patients with Crohn’s disease (CD) and ulcerative colitis (UC). The aim of this study was to evaluate long-term outcomes after switching from IV-IFX to SC-IFX, including the drug concentration thresholds for maintaining remission and other predictors for loss of response after the switch. Methods: This multicenter observational study involved CD and UC patients who were in clinical remission for at least 24 weeks and were scheduled to switch from IV-IFX to SC-IFX. Results: Two hundred and twenty patients were included (74 UC [34%] and 146 CD [66%]). IV-IFX was administered for 52.5 months (range 25-89). Before switch, 106 (49%) patients were receiving intensified IV-IFX. While SC-IFX levels significantly increased following the switch from IV-IFX to SC-IFX, clinical parameters, C-reactive protein, and fecal calprotectin remained unchanged during follow-up. SC-IFX levels were significantly higher in patients receiving the standard IV-IFX dose than in those receiving the intensified dose. Immunomodulatory therapy at baseline and perianal disease had no effect on IFX trough levels, whereas higher body mass index was associated with increased levels. The suggested optimal SC-IFX cutoff concentration for clinical and biochemical remissions based on receiver operating characteristic analysis was 12.2 μg/mL (area under the curve [AUC]: 0.62) at Week 12 and 13.2 μg/mL (AUC: 0.57) at Week 52. Drug persistence was 92% at Week 52, with a good safety profile. Conclusions: Switching from IV-IFX to SC-IFX safely maintains long-term remission in patients with CD and UC. In maintenance, the optimal cutoff point associated with remission was 12-13 μg/mL.


  • HIV Infection Is Associated With a Less Aggressive Phenotype of Inflammatory Bowel Disease: A Multicenter Study of the ENEIDA Registry

    by Margalida Calafat, Carles Suria, Francisco Mesonero, Ruth de Francisco, Carmen Yagüe Caballero, Luisa de la Peña, Alejandro Hernández-Camba, Ainhoa Marcé, Beatriz Gallego, Noelia Martín-Vicente, et al.

    INTRODUCTION: The coexistence of HIV infection and inflammatory bowel disease (IBD) is uncommon. Data on the impact of HIV on IBD course and its management are scarce. The aim of this study was to describe the IBD phenotype, therapeutic requirements, and prevalence of opportunistic infections (OIs) in IBD patients with a coexistent HIV infection. METHODS: Case-control, retrospective study includes all HIV-positive patients diagnosed with IBD in the Nationwide study on genetic and environmental determinants of inflammatory bowel disease registry. Patients with positive HIV serology (HIV-IBD) were compared with controls (HIV seronegative), matched 1:3 by year of IBD diagnosis, age, sex, and type of IBD. RESULTS: A total of 364 patients (91 HIV-IBD and 273 IBD controls) were included. In the whole cohort, 58% had ulcerative colitis, 35% had Crohn's disease (CD), and 7% were IBD unclassified. The HIV-IBD group presented a significantly higher proportion of proctitis in ulcerative colitis and colonic location in CD but fewer extraintestinal manifestations than controls. Regarding treatments, nonbiological therapies (37.4% vs 57.9%; P = 0.001) and biologicals (26.4% vs 42.1%; P = 0.007), were used less frequently among patients in the HIV-IBD group. Conversely, patients with HIV-IBD developed more OI than controls, regardless of nonbiological therapy use. In the multivariate analysis, HIV infection (odds ratio 4.765, 95% confidence interval (CI) 2.48–9.14; P < 0.001) and having ≥1 comorbidity (OR 2.445, 95% CI 1.23–4.85; P = 0.010) were risk factors for developing OI, while CD was protective (OR 0.372, 95% CI 0.18–0.78; P = 0.009). DISCUSSION: HIV infection seems to be associated with a less aggressive phenotype of IBD and a lesser use of nonbiological therapies and biologicals but entails a greater risk of developing OI.


  • Open Access

    Combination of granulocyte–monocyte apheresis and ustekinumab: Multicentre and retrospective study

    by Iago Rodríguez-Lago, Claudia Herrera-Deguise, Maia Boscá-Watts, Cristina Rodríguez, Eduardo Leo-Carnerero, María Calvo Íñiguez, Fiorella Cañete, Silvia Chacón, Camila Cuarán, Ainara Elorza, et al.

  • Biological treatment interruption in inflammatory bowel disease: Motivation and predictive factors

    by María Rocío Davis González, María Pilar Ballester, Eva Romero-González, Ana María Sánchez-Pardo, David Marti-Aguado, Joan Tosca, Carles Suria, Rosario Antón Ausejo, Isabel Pascual Moreno, María Dolores Planelles Silvestre, et al.

  • Open Access

    Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP

    by Cristina Rubín de Célix, Javier Martín-De-Carpi, Gemma Pujol-Muncunill, Laura María Palomino, Marta Velasco Rodríguez-Belvís, Rafael Martín-Masot, Víctor Manuel Navas-López, Elena Ricart, María José Casanova, Alejandro Rodríguez-Martínez, et al.

    (1) Background: Transition is a planned movement of paediatric patients to adult healthcare systems, and its implementation is not yet established in all inflammatory bowel disease (IBD) units. The aim of the study was to evaluate the impact of transition on IBD outcomes. (2) Methods: Multicentre, retrospective and observational study of IBD paediatric patients transferred to an adult IBD unit between 2017–2020. Two groups were compared: transition (≥1 joint visit involving the gastroenterologist, the paediatrician, a programme coordinator, the parents and the patient) and no-transition. Outcomes within one year after transfer were analysed. The main variable was poor clinical outcome (IBD flare, hospitalisation, surgery or any change in the treatment because of a flare). Predictive factors of poor clinical outcome were identified with multivariable analysis. (3) Results: A total of 278 patients from 34 Spanish hospitals were included. One hundred eighty-five patients (67%) from twenty-two hospitals (65%) performed a structured transition. Eighty-nine patients had poor clinical outcome at one year after transfer: 27% in the transition and 43% in the no-transition group (p = 0.005). One year after transfer, no-transition patients were more likely to have a flare (36% vs. 22%; p = 0.018) and reported more hospitalisations (10% vs. 3%; p = 0.025). The lack of transition, as well as parameters at transfer, including IBD activity, body mass index < 18.5 and corticosteroid treatment, were associated with poor clinical outcome. One patient in the transition group (0.4%) was lost to follow-up. (4) Conclusion: Transition care programmes improve patients’ outcomes after the transfer from paediatric to adult IBD units. Active IBD at transfer impairs outcomes.


  • Open Access

    Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    by Yamile Zabana, Ignacio Marín-Jiménez, Iago Rodríguez-Lago, Isabel Vera, María Dolores Martín-Arranz, Iván Guerra, Javier P. Gisbert, Francisco Mesonero, Olga Benítez, Carlos Taxonera, et al.

    (1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to assess these differences between infected and noninfected patients with IBD. (2) This nationwide case–control study evaluated patients with inflammatory bowel disease with COVID-19 (cases) and without COVID-19 (controls) during the period March–July 2020 included in the ENEIDA of GETECCU. (3) A total of 496 cases and 964 controls from 73 Spanish centres were included. No differences were found in the basal characteristics between cases and controls. Cases had higher comorbidity Charlson scores (24% vs. 19%; p = 0.02) and occupational risk (28% vs. 10.5%; p < 0.0001) more frequently than did controls. Lockdown was the only protective measure against COVID-19 (50% vs. 70%; p < 0.0001). No differences were found in the use of systemic steroids, immunosuppressants or biologics between cases and controls. Cases were more often treated with 5-aminosalicylates (42% vs. 34%; p = 0.003). Having a moderate Charlson score (OR: 2.7; 95%CI: 1.3–5.9), occupational risk (OR: 2.9; 95%CI: 1.8–4.4) and the use of 5-aminosalicylates (OR: 1.7; 95%CI: 1.2–2.5) were factors for COVID-19. The strict lockdown was the only protective factor (OR: 0.1; 95%CI: 0.09–0.2). (4) Comorbidities and occupational exposure are the most relevant factors for COVID-19 in patients with IBD. The risk of COVID-19 seems not to be increased by immunosuppressants or biologics, with a potential effect of 5-aminosalicylates, which should be investigated further and interpreted with caution.